Rakesh Nagilla

Discovery of a First-in-Class Receptor Interacting Protein 1 (RIP1) Kinase Specific Clinical Candidate (GSK2982772) for the Treatment of Inflammatory Diseases

Philip A. Harris, Scott B. Berger, Jae Uk Jeong et al. · Journal of Medicinal Chemistry · 2017 · 464 citations · Full text

Drug Target, Immunology, Cell Death +22

DNA-Encoded Library Screening Identifies Benzo[<i>b</i>][1,4]oxazepin-4-ones as Highly Potent and Monoselective Receptor Interacting Protein 1 Kinase Inhibitors

Philip A. Harris, Bryan W. King, Deepak Bandyopadhyay et al. · Journal of Medicinal Chemistry · 2016 · 268 citations · Full text

Drug Target, Immunology, Kinase Inhibitors +17

AMTB, a TRPM8 channel blocker: evidence in rats for activity in overactive bladder and painful bladder syndrome

Erin S. R. Lashinger, Matthew S. Steiginga, J. Paul Hieble et al. · American Journal of Physiology-Renal Physiology · 2008 · 204 citations

Characterization of GSK′963: a structurally distinct, potent and selective inhibitor of RIP1 kinase

SB Berger, Philip A. Harris, Rakesh Nagilla et al. · Cell Death Discovery · 2015 · 145 citations · Full text

Discovery of Small Molecule RIP1 Kinase Inhibitors for the Treatment of Pathologies Associated with Necroptosis

Philip A. Harris, Deepak Bandyopadhyay, Scott B. Berger et al. · ACS Medicinal Chemistry Letters · 2013 · 135 citations · Full text

Pathologies Associated, Apoptosis, Immunology +24